Literature DB >> 22230329

Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.

Michelle C Vendel1, Michael Favis, William B Snyder, Flora Huang, Allan D Capili, Jianying Dong, Scott M Glaser, Brian R Miller, Stephen J Demarest.   

Abstract

Escherichia coli (E. coli) is the most commonly used organism for expressing antibody fragments such as single chain antibody Fvs (scFvs). Previously, we have utilized E. coli to express well-folded scFvs for characterization and engineering purposes with the goal of using these engineered proteins as building blocks for generating IgG-like bispecific antibodies (BsAbs). In the study, described here, we observed a significant difference in the secondary structure of an scFv produced in E. coli and the same scFv expressed and secreted from chinese hamster ovary (CHO) cells as part of a BsAb. We devised a proteolytic procedure to separate the CHO-derived scFv from its antibody-fusion partner and compared its properties with those of the E. coli-derived scFv. In comparison to the CHO-derived scFv, the E. coli-derived scFv was found trapped in a misfolded, but monomeric state that was stable for months at 4 °C. The misfolded state bound antigen in a heterogeneous fashion that included non-specific binding, which made functional characterization challenging. This odd incidence of obtaining a misfolded scFv from bacteria suggests careful characterization of the folded properties of bacterially expressed scFvs is warranted if anomalous issues with antigen-binding or non-specificity occur during an engineering campaign. Additionally, our proteolytic methodology for obtaining significant levels of intact scFvs from highly expressed IgG-like antibody proteins serves as a robust method for producing scFvs in CHO without the use of designed cleavage motifs.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230329     DOI: 10.1016/j.abb.2011.12.018

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

1.  Simultaneous surface display and secretion of proteins from mammalian cells facilitate efficient in vitro selection and maturation of antibodies.

Authors:  Robert A Horlick; John L Macomber; Peter M Bowers; Tamlyn Y Neben; Geoffery L Tomlinson; Irina P Krapf; Jennifer L Dalton; Petra Verdino; David J King
Journal:  J Biol Chem       Date:  2013-05-20       Impact factor: 5.157

2.  Different expression systems resulted in varied binding properties of anti-paclitaxel single-chain variable fragment antibody clone 1C2.

Authors:  Gorawit Yusakul; Seiichi Sakamoto; Poomraphie Nuntawong; Hiroyuki Tanaka; Satoshi Morimoto
Journal:  J Nat Med       Date:  2017-10-12       Impact factor: 2.343

3.  Plant-made antibody against miroestrol: a new platform for expression of full-length immunoglobulin G against small-molecule targets in immunoassays.

Authors:  Kaewta Rattanapisit; Tharita Kitisripanya; Atthaphon Konyanee; Worapol Sae-Foo; Apisit Burapapiruin; Waraporn Putalun; Seiichi Sakamoto; Waranyoo Phoolcharoen; Gorawit Yusakul
Journal:  Plant Cell Rep       Date:  2021-02-13       Impact factor: 4.570

4.  High affinity humanized antibodies without making hybridomas; immunization paired with mammalian cell display and in vitro somatic hypermutation.

Authors:  Audrey D McConnell; Minjee Do; Tamlyn Y Neben; Vladimir Spasojevic; Josh MacLaren; Andy P Chen; Laurence Altobell; John L Macomber; Ashley D Berkebile; Robert A Horlick; Peter M Bowers; David J King
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

5.  Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding.

Authors:  Chunyu Wang; Yanling Wu; Lili Wang; Binbin Hong; Yujia Jin; Dan Hu; Gang Chen; Yu Kong; Ailing Huang; Guoqiang Hua; Tianlei Ying
Journal:  Front Immunol       Date:  2017-11-13       Impact factor: 7.561

Review 6.  Design and Production of Bispecific Antibodies.

Authors:  Qiong Wang; Yiqun Chen; Jaeyoung Park; Xiao Liu; Yifeng Hu; Tiexin Wang; Kevin McFarland; Michael J Betenbaugh
Journal:  Antibodies (Basel)       Date:  2019-08-02

7.  Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab®.

Authors:  Justyna Jureczek; Anja Feldmann; Ralf Bergmann; Claudia Arndt; Nicole Berndt; Stefanie Koristka; Liliana Rodrigues Loureiro; Nicola Mitwasi; Anja Hoffmann; Alexandra Kegler; Tabea Bartsch; Michael Bachmann
Journal:  Onco Targets Ther       Date:  2020-06-12       Impact factor: 4.147

Review 8.  Development of bispecific antibodies in China: overview and prospects.

Authors:  Jing Zhang; Jizu Yi; Pengfei Zhou
Journal:  Antib Ther       Date:  2020-05-30

9.  Designing and generating a single-chain fragment variable (scFv) antibody against IL2Rα (CD25): An in silico and in vitro study.

Authors:  Parnian Navabi; Mohamad Reza Ganjalikhany; Sepideh Jafari; Moein Dehbashi; Mazdak Ganjalikhani-Hakemi
Journal:  Iran J Basic Med Sci       Date:  2021-03       Impact factor: 2.699

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.